Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Status:
Completed
Trial end date:
2019-05-22
Target enrollment:
Participant gender:
Summary
This study has two parts, dose escalation and dose expansion. For dose escalation, the
primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with
uveal melanoma. For dose expansion, the primary objective is to characterize the safety and
tolerability of the MTD of AEB071 in patients with uveal melanoma.